Anzeige
Mehr »
Montag, 20.07.2026 - Börsentäglich über 12.000 News
DER COUNTDOWN LÄUFT: 42 Proben im Labor - Jetzt beginnt die spannendste Phase für diese Wolfram-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A422GY | ISIN: US72941H8060 | Ticker-Symbol: XMP1
Frankfurt
17.07.26 | 08:01
3,310 Euro
-4,34 % -0,150
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoPlus Therapeutics partners with GTC on CSF diagnostic platform15
DoPlus Therapeutics Inc.: Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide CSF Assay Platform188HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration...
► Artikel lesen
DiPlus Therapeutics Inc.: Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring190HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network (NCCN)...
► Artikel lesen
01.07.Plus Therapeutics rebrands as Cerenome as it deepens AI strategy3
30.06.Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY3
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
30.06.Plus Therapeutics Inc.: Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding347Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide commercial progress HOUSTON, June 30...
► Artikel lesen
25.06.Plus Therapeutics wins Elevance Health coverage deal3
25.06.CNSide signs coverage deal with Elevance Health for 45.4M4
25.06.Plus Therapeutics Inc.: Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer4
23.06.Plus Therapeutics Inc.: Plus Therapeutics to Provide Business Update Call on June 30, 20264
18.06.PLUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans13
05.06.PLUS THERAPEUTICS, INC. - 8-K, Current Report6
04.06.CNSide Diagnostics receives laboratory accreditation from CAP1
04.06.Plus Therapeutics Inc.: Plus Therapeutics Announces CAP Accreditation of CNSide Diagnostics Clinical Laboratory7
26.05.Plus Therapeutics Inc.: Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases19
19.05.Plus Therapeutics partners with Ephemeral on AI platform5
19.05.Plus Therapeutics kooperiert mit Ephemeral bei KI-Plattform für die Onkologie5
19.05.Plus Therapeutics Inc.: Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology2
15.05.Plus Therapeutics GAAP EPS of -$1.05 misses by $0.15, revenue of $1.03M beats by $0.06M2
15.05.Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates4
Weiter >>
85 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1